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Background: Undiagnosed allergic bronchopulmonary aspergillosis (ABPA) can lead to chronic persistent 
symptoms. In country like Pakistan where tuberculosis (TB) is endemic, a significant proportion of ABPA patients 
are misdiagnosed as smear negative TB before reaching a diagnosis of ABPA due to chronicity of symptoms.This 
lead to empiric use of ATT(Anti-tuberculous therapy) and delay in primary diagnosis. The aim of the study is to 
determine such proportion of ABPA patients. 
Material and methods: This retrospective study was conducted at the outpatient pulmonology clinic of a tertiary 
care hospital in Karachi, Pakistan from January 2017 to December 2018. Xpert MTB/Rif, TB smear and culture 
were performed in all patients to rule out active TB. 
Results: A total 167 of ABPA patients were included. Mean age of the patients was 41.9 ± 13.0 years, 91(54.5%) 
were female and 71 (42.5%) patients had received ATT in past. Out of these 71 patients, 63 (88.7%) patients 
were diagnosed as smear negative TB and received empiric ATT. Among 63 patients, 52 (82.5%) patient had 
received ATT once, 8 (12.6%) twice and 3 (4.7%) patients had received empiric ATT thrice. Of these 27 (16.16%) 
patients had already developed long term complications at the time of diagnosis of ABPA and 17 (62.96%) 
patients were in empiric TB treatment group. 
Conclusion: Patient with ABPA frequently received empiric ATT as smear negative TB in high TB burden country. 
This results in over diagnosis of TB and unnecessary use of global resource. When Gene Xpert negative alternate 
diagnosis should be considered.   
1. Introduction 
Allergic bronchopulmonary aspergillosis (ABPA) occurs due to hy-
persensitivity reactions in response to colonization of the tracheobron-
chial tree by Aspergillus spp [1]. Around 1–2% patients with asthma and 
2–15% patients with cystic fibrosis are estimated to have concomitant 
ABPA [2]. Out of the reported 510,000 new cases of TB from Pakistan, 
almost 112,948 are smear negative for acid fast bacillus (AFB) [3]. Due 
to the high prevalence of TB in Pakistan, it is common to misdiagnose 
ABPA patients as smear negative TB with prolonged treatment with 
anti-tuberculous therapy (ATT) [4]. 
ABPA and TB share certain features that make it difficult to distin-
guish between these conditions. Cough, fever and hemoptysis are the 
presenting complaints in both entities. According to a study, almost 31% 
of patients with ABPA had hemoptysis as primary complaint; [5]. 
Similarly, a study on TB revealed that hemoptysis was a symptom in 
about 79.2% of patients [6]. Bilateral rhonchi, crackles and wheezes are 
common examination findings in both the diseases. Both entities can 
present with bilateral infiltrates and bronchiectasis changes. 
A delayed diagnosis of ABPA can predispose patients to a number of 
complications including bronchiectasis, pulmonary fibrosis, respiratory 
failure and progressive lung damage eventually leading to death [7]. 
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Therefor a misdiagnosis not only exposes a patient unnecessarily to ATT 
but also leads to a number of ABPA associated complications. Since 
Pakistan have high burden of TB majority of ABPA patients before 
reaching a diagnosis ended up with empiric ATT even they are Gen-
eXpert negative. In this study we have highlighted these patients who 
were treated as smear negative TB with no clinical and radiological 
improvement and later turned out to be ABPA. 
2. Material and Methods 
This was a retrospective study conducted on patients diagnosed with 
ABPA in the outpatient adult pulmonary clinic of Aga Khan University 
Hospital, (AKUH) Karachi, Pakistan from January 2017 to December 
2018. The study was exempted by the Ethical Review Committee of Aga 
Khan University Hospital. ABPA patients were identified through 
outpatient pulmonary clinic database. The diagnostic criteria for ABPA 
was adopted from ISHAM 2013 [8]. Inclusion criteria included: 1) Age 
≥18 years with underlying asthma, 2) Serum IgE level ≥1000 IU/ml, 3) 
Peripheral eosinophilia ≥500 cells/μL in steroid naïve patients, 4) 
Radiographic pulmonary opacities consistent with ABPA, 5) A positive 
type I Aspergillus skin test (immediate cutaneous hypersensitivity to 
Aspergillus antigen), 6) Active TB and other infections were ruled out by 
sputum microscopy, culture and Xpert MTB/Rif. ABPA was classified 
into five stages, stage 1 patients with acute flare, stage 2 patients who 
underwent remission, stage 3 patients with recurrent exacerbations, 
stage 4 patients who were steroids dependent and stage 5 patients with 
advanced fibrotic lung disease. Data was collected on predesigned pro-
forma which included demographics, co-morbid conditions, presenting 
clinical symptoms, smoking status, serum IgE and eosinophilia levels, 
chest X ray findings, status, duration and frequency of ATT and com-
plications developed by these patients. Patients with an incomplete re-
cord and with evidence of active TB were excluded from this study. 
3. Statistical analysis 
SPSS V.19.0 was used for data analysis. Descriptive statistics were 
done, and results are presented as mean and standard deviation for 
continuous variable and number and percentages for categorical 
variables. 
4. Results 
A total of 167 patients with a known diagnosis of ABPA were selected 
for the study. A total 167 of ABPA patients were included. Mean age of 
the patients was 41.9 ± 13.0 years, 91(54.5%) were female and 71 
(42.5%) patients had received ATT in past. Out of these 71 patients, 63 
(88.7%) patients were misdiagnosed as smear negative TB and received 
empiric ATT before diagnosing ABPA. The remaining 8 patients were 
excluded from the study due to smear positive TB. These 167 ABPA 
patients were divided into two groups those who received empiric ATT, 
misdiagnosed as smear negative TB (63 patients) and who did not 
receive ATT (96 patients). 
Both groups reported symptoms of weight loss, dyspnea, wheezing, 
chest pain, sputum pellets, cough and fever of variable duration. Cough 
and dyspnea were the most common symptoms in both groups. How-
ever, hemoptysis was the only variable that was found to be statistically 
significant in the smear negative TB group. Chest X-ray findings such as 
consolidations, nodules, cavitation, fibrosis and infiltrates were also 
found to be present in both groups. Pulmonary nodules were found to be 
the most common chest X-ray finding in both the smear negative ATT 
group and the non-ATT group (Table 1). Out of the 63 patients, 52 
(82.5%) patients had received ATT once, 8 (12.6%) patients received 
ATT twice and, 3 (4.7%) patients had received ATT therapy for a total of 
three times before reaching the diagnosis of ABPA. 
Out of 167, 27 (16.16%) patients of ABPA developed long term 
complications and 17 (62.96%) patients were in smear negative TB 
treatment group. Recurrent hemoptysis was developed in 7, chronic 
respiratory failure in 6, chronic pulmonary aspergillosis in 5 and cor- 
pulmonale in 5 patients. 
5. Discussion 
Aspergillus infection can lead to invasive and non-invasive diseases 
[9]. However, ABPA is a condition characterized by a hypersensitivity 
response to the fungus Aspergillus (most commonly Aspergillus fumigatus). 
Patient may also misdiagnosed as chronic persistent asthma [10].To our 
best of knowledge, this is the first study conducted in Pakistan on the 
misdiagnosis of ABPA with smear negative TB. Our study clearly shows 
that APBA is still under recognized in the country. Empiric ATT use is 
common and 82.5% patients had received ATT once. 
Our results are in line with similar studies in other TB endemic 
countries [11–14]. Due to the similar clinical and radiological features 
of both diseases patients with ABPA are often misdiagnosed as pulmo-
nary TB in high endemic areas [11]. Studies showed that almost one 
third of ABPA patients in India are mistakenly diagnosed as pulmonary 
TB [12]. A 2006 study in India showed that out of 126 patients pre-
senting to a chest clinic with ABPA, 59 were initially misdiagnosed as 
pulmonary TB and received ATT [12]. Similarly, a 2009 retrospective 
study revealed that 91% of patients with ABPA were initially diagnosed 
with pulmonary TB and were prescribed ATT [14]. In a 2019 study in 
China, out of 50 patients with ABPA, 5 were initially diagnosed with 
Pulmonary TB and received ATT therapy [15]. 
There is no one set method for diagnosing ABPA which is why it often 
becomes a diagnostic challenge [16]. The diagnosis is usually made 
following Rosenberg and Patterson’s criteria though patients may be 
monitored for several years before the entire diagnostic criteria is met 
[17]. Central bronchiectasis with normal peripheral bronchi is consid-
ered to be a key diagnostic finding in ABPA [18]. Currently 
high-resolution CT (HRCT) chest is the modality of choice for identifying 
bronchiectasis [19]. Unfortunately HRCT chest by itself has a poor 
specificity in distinguishing between different causes of bronchiectasis 
Table 1 
Clinical and radiological features of ABPA patients divided in two groups based 
on empirical ATT.   
ABPA(misdiagnosed) treated 
as Smear negative TB; n = 63 
(%) 
ABPA without TB 
treatment n = 97 
(%) 
p value 
Sex    
Male 29(46) 44(45.4)  
Female 34(54) 53(54.6) 0.93 
Age 39.9 ± 12.0 42.9 ± 13.6 0.16 
Co morbid    
DM 6(9.5) 14(14.4) 0.35 
HTN 6(9.5) 16(16.5) 0.24 
Duration of 
Asthma; years 
16(6–25) 15(4.5–25.5) 0.90* 
symptoms 
Weight loss 13(20.6) 22(22.7) 0.76 
Dyspnea 37(58.7) 56(57.7) 0.90 
Hemoptysis 22(34.9) 8(8.2) <0.001 
Pellet of sputum 14(22.2) 15(15.5) 0.27 
Wheezing 15(23.8) 25(25.8) 0.77 
Chest pain 18(28.6) 21(21.6) 0.31 
Cough 51(81.0) 74(76.3) 0.48 
Fever 15(23.8) 21(21.6) 0.74 
Chest X-ray 
Unilateral 9(14.3) 16(16.5)  
Bilateral 54(85.7) 81(83.5) 0.70 
Consolidation 12(19) 16(16.5) 0.67 
Nodules 16(25.4) 28(28.9) 0.63 
Cavitation 12(19) 9(9.3) 0.29 
Fleeting 
Infiltrates 
15(24) 22(23) 0.15 
Fibrosis 10(16) 12(12) 0.29 
ATT: Anti tuberculous therapy *Mann-whitney U test. 
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[20]. Our study did not find a significant association regarding radio-
logical findings in both groups, highlighting the limitations of radiology 
in diagnosing ABPA. 
If untreated, ABPA may progress to irreversible bronchi damage and 
lung fibrosis along with hemoptysis, chronic sputum production, 
pneumonias and ultimately respiratory failure [21]. In our study 27 
patients developed such complications, 17 were belonged to the smear 
negative group treated with ATT therapy. Complications such as chronic 
pulmonary aspergillosis and respiratory failure were almost equally 
found in both groups of patients. There was a significant association 
between hemoptysis and the smear negative TB group treated with ATT 
therapy. This finding can be explained by the progressive lung damage 
that occurs in ABPA patients who are misdiagnosed as pulmonary TB 
and are not appropriately treated for ABPA. 
Ideally, an acid-fast bacillus smear test can help distinguish between 
TB and ABPA, but the real challenge arises in ruling out ABPA in patients 
who are smear and Gene xpert negative for TB. The sensitivity of the 
GeneXpert in smear negative HIV patient was as high as 98% with the 
specificity of 52% [22]. While the pooled sensitivity and specificity for 
smear-negative TB documented up to 67% and 98% for GeneXpert, 73% 
and 91% for Microscopic Observation Drug Susceptibility assay (MODS) 
[23].Why such a large number were misdiagnosed despite role out of 
GeneXpert in the country? This may be because of lack of ABPA 
knowledge and delay in referral to chest specialist. This clearly eluci-
dates the importance of an early diagnosis and awareness regarding of 
ABPA. 
This study highlights that ABPA quite often misdiagnosed with TB 
and treated with empirical ATT in high TB burden country like Pakistan. 
However our study have few limitations. Since it is a retrospective study, 
we were unable to standardize the diagnostic and treatment approaches 
in the two set of groups. Our study is a single center study. Therefore, out 
study can be used as a baseline for larger multicenter studies which can 
ensure proper surveillance of ABPA and thus better control of the 
disease. 
6. Conclusion 
In summary, ABPA is an under recognized entity in Pakistan. It is 
often mistakenly diagnosed as pulmonary TB due to sharing similar 
clinical and radiological features. A prolonged diagnosis of ABPA can 
cause progressive lung damage which can lead to fibrosis and respira-
tory failure. Greater physician awareness and implementation of 
appropriate diagnostic criteria is essential for a timely diagnosis of 
ABPA. 
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